Brind.
  1. Penumbra was acquired by Boston Scientific in a $14.5bn deal, and the company gained clearance for its Thunderbolt product line.

Boston Scientific Prices $3B USD and €4.25B Euro Note Offerings

1 report, 1 independent Updated Nov 1
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Boston Scientific Corporation announced two public offerings of notes. The company priced a $3 billion USD offering, consisting of various senior notes due between 2029 and 2036. Additionally, American Medical Systems Europe B.V., a subsidiary, priced a €4.25 billion Euro offering, which includes notes due up to 2046.

From prnewswire.com

Why it matters

Some supportBrind's analysis of the reports

The dual financing efforts provide Boston Scientific with substantial capital. This funding occurs within the context of the company's $14.5 billion acquisition of Penumbra, which also gained clearance for its Thunderbolt product line.

Penumbra was acquired by Boston Scientific in a $14.5 billion deal, and the company gained clearance for its Thunderbolt product line.

From prnewswire.com

Who's involved

Keep exploring

Coverage

Newest first; wire copies grouped